Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DM3NUMH)
Drug Name | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
|
|||||||||||||||||||||||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||||||||||||||||||||||
Therapeutic Class |
Antipsychotic Agents
|
|||||||||||||||||||||||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||||||||||||||||||||||
Molecule(s) Related to This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
|||||||||||||||||||||||||||||||||||||||||
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
|
|||||||||||||||||||||||||||||||||||||||||||||||
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | |||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
ICD Disease Classification | 06 Mental, behavioural or neurodevelopmental disorder | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Disease Class | ICD-11: 6A20 Schizophrenia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Studied Tissue | Pre-frontal cortex | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Studied Disease | Schizophrenia [ICD-11:6A20] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References